Allurion Technologies (ALUR) announced a new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry. The company signed a term sheet with a strategic partner for ex-US distribution and R&D, including a potential GLP-1 drug-eluting balloon. Allurion also submitted a protocol for a clinical trial on its program combined with a low-dose GLP-1 and reported its PMA application for the Allurion Balloon was accepted by the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR: